Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL-87 vs Codeine
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a synthetic opioid that primarily acts as a mu-opioid receptor agonist, inhibiting adenylate cyclase, decreasing c AMP production, and modulating ion channels (calcium, potassium) to reduce neurotransmitter release and neuronal excitability.
Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. It is a prodrug converted to morphine via CYP2D6, which mediates most of its analgesic effects.
Management of severe acute pain in opioid-tolerant patients requiring opioid analgesia,Anesthesia induction and maintenance,Supplemental analgesia during regional anesthesia,Procedural sedation and analgesia (off-label),Chronic pain management in opioid-tolerant patients (off-label)
FDA-approved for mild to moderate pain where an opioid is appropriate,FDA-approved for cough suppression,Off-label: acute pain, chronic pain (limited use)
IV: 0.5-2 mcg/kg as a bolus; continuous infusion: 0.7-10 mcg/kg/hr. Transdermal: 25-100 mcg/h every 72 hours. Transmucosal (buccal or lozenge): 200-1600 mcg as a single dose.
Oral: 30-60 mg every 4-6 hours as needed; maximum 360 mg per day. Intramuscular/Subcutaneous: 30-60 mg every 4-6 hours as needed. Use lowest effective dose for shortest duration.
Terminal elimination half-life is approximately 3–12 hours (mean 7 hours) in adults; prolonged to up to 20–30 hours in elderly, critically ill, or patients with hepatic impairment. Context-sensitive half-life increases with infusion duration.
The terminal elimination half-life of codeine is approximately 2.5 to 3.5 hours in adults with normal renal function. In patients with renal impairment, the half-life may be prolonged to up to 8 hours, necessitating dose adjustment.
Fentanyl undergoes extensive hepatic metabolism via CYP3A4-mediated N-dealkylation to norfentanyl, along with other minor pathways; elimination is primarily renal.
Codeine is metabolized by CYP2D6 to morphine (active), via CYP3A4 to norcodeine (inactive), and via glucuronidation. Morphine is further conjugated via UGT2B7.
Primarily hepatic metabolism (>90%) to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for approximately 75% of total elimination, with about 9% excreted unchanged in urine. Fecal excretion is minimal (<9%).
Codeine is eliminated primarily via renal excretion (about 90% as inactive metabolites, mainly codeine-6-glucuronide and norcodeine, with less than 10% as free codeine). Biliary/fecal excretion accounts for approximately 10% of the dose.
Approximately 80–85% bound to plasma proteins (primarily alpha-1-acid glycoprotein and albumin). Increased free fraction in hypoalbuminemia.
Approximately 25% bound to plasma proteins, primarily albumin.
4–6 L/kg (large, extensive tissue distribution). High Vd reflects rapid redistribution from blood to tissues (muscle, fat).
Approximately 3-6 L/kg, indicating extensive distribution into tissues, including brain and breast milk.
Intravenous: 100%; intramuscular: ~90%; oral transmucosal: ~50% (range 25–70%, first-pass hepatic metabolism); intranasal: ~50–90%; transdermal: ~30–50% (variable, rate-limited by skin barrier).
Oral bioavailability is about 60-90% (first-pass metabolism reduces systemic exposure; extensive metabolizers may have higher morphine levels). Rectal bioavailability is similar to oral. Intramuscular and subcutaneous routes have nearly 100% bioavailability.
No specific dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider dose reduction by 50% or increase dosing interval. Caution in renal impairment due to potential accumulation of metabolites.
Cr Cl 10-50 m L/min: Administer 75% of normal dose. Cr Cl <10 m L/min: Administer 50% of normal dose. Not recommended in severe renal impairment due to risk of CNS toxicity.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Use with caution; consider 75% dose reduction. Monitor for prolonged effect.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% or use alternative. Child-Pugh Class C: Contraindicated. Avoid in severe hepatic impairment due to decreased metabolism and risk of accumulation.
IV bolus: 1-2 mcg/kg for analgesia; for sedation/analgesia: 1-2 mcg/kg followed by infusion 0.5-2 mcg/kg/hr. Transdermal: Not recommended for opioid-naive pediatric patients. Transmucosal: Not recommended for children under 2 years.
Oral, IM, or SC: 0.5-1 mg/kg/dose every 4-6 hours as needed; maximum 60 mg/dose. Weight-based dosing for children >1 year. Not recommended in children under 12 years for postoperative tonsillectomy/adenoidectomy. Contraindicated in children <12 years for pain, and <18 for cough due to risk of respiratory depression.
Reduce initial dose by 50% compared to younger adults. Titrate slowly; monitor for respiratory depression and constipation. Consider using lower strength transdermal patches (12 mcg/h or 25 mcg/h).
Start at low end of dosing range (e.g., 30 mg every 4-6 hours) due to increased sensitivity and risk of respiratory depression, falls, and cognitive impairment. Monitor renal function and avoid in patients with Cr Cl <30 m L/min. Consider non-opioid alternatives first.
Fentanyl carries a risk of respiratory depression, abuse, misuse, addiction, and diversion. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death. Neonatal opioid withdrawal syndrome may occur with prolonged use during pregnancy.
WARNING: CODEFINE HAS RISKS OF ADDICTION, ABUSE, AND MISUSE, WHICH CAN LEAD TO OVERDOSE AND DEATH. LIFE-THREATENING RESPIRATORY DEPRESSION MAY OCCUR, ESPECIALLY IN CHILDREN, AND RISK IS INCREASED WITH CYP2D6 ULTRA-RAPID METABOLIZERS. PROLONGED USE DURING PREGNANCY CAN RESULT IN NEONATAL OPIOID WITHDRAWAL SYNDROME.
Life-threatening respiratory depression; risk of serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; severe hypotension; bradycardia; use in patients with head injuries or increased intracranial pressure; opioid-induced hyperalgesia; withdrawal if abruptly discontinued.
CYP2D6 ultra-rapid metabolizers: risk of morphine toxicity, fatal respiratory depression,Life-threatening respiratory depression in children <12 years; contraindicated in <18 years for tonsillectomy/adenoidectomy,Risk of opioid-induced respiratory depression, especially in elderly, debilitated, or patients with respiratory conditions,Addiction, abuse, and misuse potential,Neonatal opioid withdrawal syndrome if used during pregnancy,Concomitant use with CNS depressants increases risk of hypotension, respiratory depression, and coma,Serotonin syndrome with serotonergic drugs,Severe hypotension, including orthostatic hypotension,Adrenal insufficiency with prolonged use,Increased risk of seizures in patients with seizure disorders,May impair ability to drive or operate machinery
Significant respiratory depression; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of such therapy; hypersensitivity to fentanyl.
Hypersensitivity to codeine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Paralytic ileus (known or suspected),Postoperative management in children <18 years after tonsillectomy/adenoidectomy,Children <12 years,Use with MAOIs or within 14 days of stopping MAOIs
No significant food interactions have been reported. However, fentanyl should be taken on an empty stomach only when specified by the prescriber for transmucosal formulations. Grapefruit juice may theoretically increase fentanyl levels due to CYP3A4 inhibition, but clinical significance is minimal; avoid large amounts.
Avoid alcohol completely; increase risk of CNS depression and hepatotoxicity. Grapefruit juice may inhibit CYP3A4, affecting codeine metabolism; limited data but caution advised. High-fiber foods may help counteract constipation. No significant food restrictions aside from alcohol.
First trimester: Limited human data; animal studies show increased risk of neural tube defects at high doses. Second/third trimester: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome; avoid prolonged high-dose use.
FDA Pregnancy Category C. First trimester: association with neural tube defects, cleft palate; second/third trimester: risk of fetal dependence, respiratory depression, withdrawal after birth. Avoid in labor due to neonatal respiratory depression.
Fentanyl is excreted in breast milk; M/P ratio approximately 0.4. Low concentrations in milk; use with caution in neonates due to potential respiratory depression or withdrawal.
Codeine is excreted into breast milk; M/P ratio approximately 2.0. Use with caution; risk of infant opioid toxicity, especially in CYP2D6 ultra-rapid metabolizers. Not recommended for breastfeeding mothers.
Pregnancy increases clearance and volume of distribution; may require higher doses for analgesia in third trimester; monitor for reduced effect and adjust accordingly.
Increased clearance and volume of distribution in pregnancy may require higher doses for analgesia; however, avoid due to risks. No standard adjustment; use lowest effective dose for shortest duration if necessary.
Fentanyl is 50-100 times more potent than morphine. For opioid-naive patients, start with the lowest effective dose. Monitor for respiratory depression, especially during initiation and dose titration. Consider co-administration of naloxone for home use in patients at high risk for overdose (e.g., high doses, concurrent benzodiazepine use). Transdermal patches are contraindicated in acute pain due to slow onset. Do not heat or cut fentanyl patches. In patients with renal impairment, fentanyl is preferred over morphine due to lack of active metabolites that accumulate.
Codeine is a prodrug requiring CYP2D6 metabolism to morphine; poor metabolizers have reduced efficacy, while ultra-rapid metabolizers risk toxicity. Avoid in children <12 years for post-tonsillectomy/adenoidectomy due to fatal respiratory depression. Monitor for constipation; prescribe laxative with chronic use. Contraindicated with MAOIs and within 14 days of their discontinuation. Not effective for acute pain needing immediate relief due to variable conversion.
Do not stop taking this medication abruptly; it may cause withdrawal symptoms.,Do not drive or operate heavy machinery until you know how fentanyl affects you.,Keep this medication in a safe place away from children and pets.,Do not consume alcohol or sedatives while taking fentanyl.,Seek emergency medical help if you have trouble breathing, excessive drowsiness, or fainting.,Do not apply heat (heating pad, hot tub) to the patch site as it may increase absorption.,Dispose of used patches by folding adhesive sides together and flushing down toilet.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not combine with alcohol, sedatives, or other CNS depressants (e.g., benzodiazepines) due to risk of severe drowsiness, respiratory depression, or coma.,Common side effects include constipation, nausea, dizziness, and drowsiness. Drink plenty of fluids and consider stool softeners for constipation.,Avoid driving or operating machinery until you know how codeine affects you, as it may impair judgment and coordination.,Inform your doctor if you have a history of asthma, breathing problems, liver or kidney disease, or if you are pregnant or breastfeeding.,Do not share this medication with others, especially children; accidental use can be fatal. Store securely out of reach of children.,If you miss a dose, take it as soon as you remember. If near the next dose, skip the missed one; do not double dose.,Do not stop abruptly after prolonged use; taper under medical supervision to avoid withdrawal symptoms (anxiety, sweating, insomnia, diarrhea).
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTANYL-87 vs Codeine, answered by our medical review team.
FENTANYL-87 is a Opioid Agonist that works by Fentanyl is a synthetic opioid that primarily acts as a mu-opioid receptor agonist, inhibiting adenylate cyclase, decreasing c AMP production, and modulating ion channels (calcium, potassium) to reduce neurotransmitter release and neuronal excitability.. Codeine is a Opioid Agonist that works by Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. It is a prodrug converted to morphine via CYP2D6, which mediates most of its analgesic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL-87 and Codeine depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL-87 is: IV: 0.5-2 mcg/kg as a bolus; continuous infusion: 0.7-10 mcg/kg/hr. Transdermal: 25-100 mcg/h every 72 hours. Transmucosal (buccal or lozenge): 200-1600 mcg as a single dose.. The standard adult dose of Codeine is: Oral: 30-60 mg every 4-6 hours as needed; maximum 360 mg per day. Intramuscular/Subcutaneous: 30-60 mg every 4-6 hours as needed. Use lowest effective dose for shortest duration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FENTANYL-87 and Codeine. The risk or severity of adverse effects can be increased when Codeine is combined with Fentanyl. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FENTANYL-87 is classified as Category D/X. First trimester: Limited human data; animal studies show increased risk of neural tube defects at high doses. Second/third trimester: Chronic use may cause fetal opioid dependence . Codeine is classified as Category D/X. FDA Pregnancy Category C. First trimester: association with neural tube defects, cleft palate; second/third trimester: risk of fetal dependence, respiratory depression, withdrawal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.